C
바이오톡스텍
086040KOSDAQ48.0 / 100
Reference Date: 2026-10-23
Financial Score17.5 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 10.9% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
BioToxtek specializes in non-clinical CRO services, conducting toxicity and safety/efficacy evaluations using rodents and primates for pharmaceuticals, cell therapies, and chemicals. The company actively participates in new material development and is advancing the commercialization of therapeutic candidates like TB-4 and HX-1171 through technology licensing.
Number of Employees
241people
Average Salary
47.0M KRW
Score Calculation Basis
Detailed Financial Score
PER
27.70Industry Average 15.001.5Point
1.8x industry avg (risky)
PBR
1.02Industry Average 1.204.0Point
In line with industry avg
ROE
-4.74Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
44.42Industry Average 100.006.5Point
Half of industry avg (excellent)
Trend 2023~20255.5 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲20.2% (2-year basis)
Operating Profit Growth Rate
2.5 / 3
Avg ▲18.7% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -18.2% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (3%, downtrend)
Current 2,050Won52-week high 3,92552-week low 1,983
1-month return1.0Point
1m -10.87% (falling)
Volume trend6.0Point
Volume increasing
Detailed Disclosure
2 totalPositive 0Neutral 2Negative 0
- Neutral기업설명회(IR)개최2026-10-20
- Neutral신주인수권부사채(해외신주인수권부사채포함)발행후만기전사채취득2026-10-08